N-Zyme Biomedical has closed an approximately US$4.6 million Series A financing to support the clinical development of its experimental treatments for reflux disease. The Delaware-headquartered biotechnology company said the funding will accelerate two Phase 2 programs focused on laryngopharyngeal reflux, commonly called LPR, and gastroesophageal reflux disease that does not respond adequately to proton pump inhibitors. The financing also gives the company resources for regulatory work, manufacturing preparations, scientific initiatives, business development, and general corporate activities.
Series A Supports Phase 2 Expansion
According to N-Zyme, the new capital fully funds its planned Phase 2 clinical programs and represents an important step in moving its lead candidate through mid-stage development. The company has begun evaluating the candidate in patients with LPR and plans a separate Phase 2 program for people with PPI-refractory GERD. By advancing the drug across both indications, N-Zyme aims to test whether the same biological approach can address persistent symptoms in different forms of reflux disease.
A Different Target in Reflux Disease
Most established reflux medicines work by lowering stomach acid production, but N-Zyme is developing a therapy designed to inhibit pepsin, a digestive enzyme that can damage tissue after reflux events. The company argues that acid suppression alone may not adequately address pepsin-related injury, particularly when patients continue experiencing symptoms despite standard treatment. Its program therefore seeks to intervene more directly in a mechanism that N-Zyme believes contributes to inflammation, tissue damage, and treatment-resistant disease.
Focus on Fosamprenavir
N-Zyme’s Phase 2 candidate uses fosamprenavir, a well-characterized molecule that the company is repurposing and reformulating as a pepsin inhibitor for reflux disease. Earlier research cited by the company indicates that fosamprenavir can bind to and inhibit pepsin, providing the scientific basis for testing the drug in LPR. The ongoing trial is evaluating efficacy and safety, with the company seeking clinical evidence that pepsin inhibition can produce meaningful benefits for patients.
Addressing LPR and Refractory GERD
LPR occurs when refluxed material reaches the throat and voice box, potentially causing chronic cough, throat clearing, hoarseness, difficulty swallowing, and other persistent symptoms. The condition is often described as silent reflux because many patients do not experience the classic heartburn associated with GERD, which can complicate diagnosis and treatment. N-Zyme is also targeting patients with GERD who remain symptomatic after using proton pump inhibitors, a group requiring additional therapeutic options.
Scientific and Corporate Momentum
The financing follows N-Zyme’s June 2026 launch of its Phase 2 LPR trial, led by co-founder and Chief Scientific Officer Dr. Nikki Johnston at the Medical College of Wisconsin. The company has also expanded its intellectual property portfolio with patents in the United States and Japan covering fosamprenavir and related compounds in reflux indications. These developments provide N-Zyme with a stronger foundation as it advances clinical testing and evaluates broader applications for its pepsin-targeted platform.
Leadership and Investor Support
N-Zyme was co-founded by Chief Executive Officer Franco Vigile and Johnston, combining company-building experience with research focused on reflux and pepsin biology. The Series A was supported by healthcare professionals, entrepreneurs, a venture capital group, and strategic investors, although the company did not disclose individual participants. Management described the financing as validation of its scientific strategy and said the proceeds would help generate the evidence needed to assess the platform’s therapeutic potential.
With the Series A completed, N-Zyme now has funding to execute its Phase 2 work while supporting the regulatory, manufacturing, and organizational requirements of clinical development. The company’s near-term progress will depend on whether its studies demonstrate that directly inhibiting pepsin can safely improve outcomes in LPR and PPI-refractory GERD. Positive results could establish a differentiated treatment path in a field dominated by acid-suppressing therapies, while unsuccessful findings would challenge the company’s central scientific premise.